Analytical Data
-
Gene name
FMR1NB
- Application
-
Alternative Names
Cancer/testis antigen 37 (CT37) (Sarcoma antigen NY-SAR-35)
-
Species
Human
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q8N0W7
-
Expression Region
90-183aa
-
Molecular Weight
15.4 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
FMR1NB (Fragile X Messenger Ribonucleoprotein 1 N-terminal Binding) protein is increasingly recognized for its role in the molecular mechanisms underlying various neurological disorders, particularly Fragile X syndrome, the most common form of inherited intellectual disability. The FMR1 gene, which encodes the FMRP protein, is crucial for synaptic function and plasticity, and mutations in this gene lead to abnormal brain development and cognitive impairment. Research has shown that FMR1NB interacts with FMRP and may influence its function, thereby impacting mRNA transport and translation in neurons. Understanding the structure and dynamics of the FMR1NB protein is essential for elucidating its potential role in neurodevelopmental processes and its therapeutic implications. Investigating FMR1NB's interactions and functional pathways could provide new insights into the molecular biology of Fragile X syndrome and related disorders, paving the way for innovative interventions. As such, the characterization of FMR1NB through recombinant techniques holds promise for advancing knowledge in neurobiology, enhancing our understanding of protein interactions, and potentially guiding the development of disease-modifying therapies.
